S&P Futures
3,796.75+6.25(+0.16%)Dow Futures
30,821.00-7.00(-0.02%)Nasdaq Futures
13,056.00+70.50(+0.54%)
Intercept Pharmaceuticals, Inc. (ICPT)
Chart Events
Performance Outlook
| Previous Close | 27.45 |
| Open | 27.68 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 800 |
| Day's Range | 26.84 - 28.95 |
| 52 Week Range | 23.78 - 105.56 |
| Volume | 1,069,990 |
| Avg. Volume | 1,023,069 |
| Market Cap | 926.757M |
| Beta (5Y Monthly) | 1.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -9.75 |
| Earnings Date | Feb 23, 2021 - Mar 01, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 52.26 |
Fair Value
Related Research
- GlobeNewswire
Intercept Appoints Jared M. Freedberg as General Counsel and Secretary
NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Jared M. Freedberg as General Counsel and Secretary. Mr. Freedberg joins Intercept from Immunomedics, Inc., which was acquired by Gilead Sciences in October of 2020. “I am very pleased to welcome Jared to the Intercept team as we begin a pivotal year for the company,” said Jerry Durso, President and Chief Executive Officer of Intercept. “His substantial legal and business development expertise will be invaluable as we focus on enhancing the growth of our foundational PBC business, supporting our NASH regulatory process in the United States and Europe, and building our pipeline.”Mr. Freedberg was previously General Counsel and Secretary and a member of the Executive Leadership Team for Immunomedics, with responsibility for management of all legal activities, including compliance, securities, corporate and board governance, contracting, IP strategy and management, business development and litigation management. While at Immunomedics, he was part of a team that successfully guided the New Drug Application for Trodelvy™ from resubmission to approval. Prior to joining Immunomedics, Mr. Freedberg served as General Counsel, Specialty Generics Operating Division, and Vice President, Business Development and Licensing at Mallinckrodt Pharmaceuticals. From 2001-2016, he held positions of increasing responsibility at Covance Inc. and was a member of Covance's Global Executive Leadership Team as Head of Strategy and Business Development from 2014-2016, during which time he led the global integration of LabCorp’s $6 billion acquisition of Covance.“I am thrilled to be joining Intercept because of the company’s unique focus on helping patients with challenging liver diseases that have limited or no treatment options,” said Mr. Freedberg. “We have a tremendous opportunity to build on the company’s strong foundation in 2021 and I look forward to being part of a team that will help shape the future of Intercept.”About Intercept Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements regarding the progress, timing and results of our clinical trials, including our clinical trials for the treatment of nonalcoholic steatohepatitis (“NASH”), the safety and efficacy of our approved product, Ocaliva (obeticholic acid or “OCA”) for primary biliary cholangitis (“PBC”), and our product candidates, including OCA for liver fibrosis due to NASH, the timing and acceptance of our regulatory filings and the potential approval of OCA for liver fibrosis due to NASH, the review of our New Drug Application for OCA for the treatment of liver fibrosis due to NASH by the U.S. Food and Drug Administration (FDA), our intent to work with the FDA to address the issues raised in the complete response letter (CRL), the potential commercial success of OCA, as well as our strategy, future operations, future financial position, future revenue, projected costs, financial guidance, prospects, plans and objectives. These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “possible,” “continue” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement except as required by law. These forward-looking statements are based on estimates and assumptions by our management that, although believed to be reasonable, are inherently uncertain and subject to a number of risks. The following represent some, but not necessarily all, of the factors that could cause actual results to differ materially from historical results or those anticipated or predicted by our forward-looking statements: our ability to successfully commercialize Ocaliva for PBC; our ability to maintain our regulatory approval of Ocaliva for PBC in the United States, Europe, Canada, Israel, Australia and other jurisdictions in which we have or may receive marketing authorization; our ability to timely and cost-effectively file for and obtain regulatory approval of our product candidates on an accelerated basis or at all, including OCA for liver fibrosis due to NASH following the issuance of the CRL by the FDA; any advisory committee recommendation or dispute resolution determination that our product candidates, including OCA for liver fibrosis due to NASH, should not be approved or approved only under certain conditions; any future determination that the regulatory applications and subsequent information we submit for our product candidates, including OCA for liver fibrosis due to NASH, do not contain adequate clinical or other data or meet applicable regulatory requirements for approval; conditions that may be imposed by regulatory authorities on our marketing approvals for our products and product candidates, including OCA for liver fibrosis due to NASH, such as the need for clinical outcomes data (and not just results based on achievement of a surrogate endpoint), any risk mitigation programs such as a REMS, and any related restrictions, limitations and/or warnings contained in the label of any of our products or product candidates; any potential side effects associated with Ocaliva for PBC, OCA for liver fibrosis due to NASH or our other product candidates that could delay or prevent approval, require that an approved product be taken off the market, require the inclusion of safety warnings or precautions, or otherwise limit the sale of such product or product candidate; the initiation, timing, cost, conduct, progress and results of our research and development activities, preclinical studies and clinical trials, including any issues, delays or failures in identifying patients, enrolling patients, treating patients, retaining patients, meeting specific endpoints in the jurisdictions in which we intend to seek approval or completing and timely reporting the results of our NASH or PBC clinical trials; our ability to establish and maintain relationships with, and the performance of, third-party manufacturers, contract research organizations and other vendors upon whom we are substantially dependent for, among other things, the manufacture and supply of our products, including Ocaliva for PBC and, if approved, OCA for liver fibrosis due to NASH, and our clinical trial activities; our ability to identify, develop and successfully commercialize our products and product candidates, including our ability to successfully launch OCA for liver fibrosis due to NASH, if approved; our ability to obtain and maintain intellectual property protection for our products and product candidates, including our ability to cost-effectively file, prosecute, defend and enforce any patent claims or other intellectual property rights; the size and growth of the markets for our products and product candidates and our ability to serve those markets; the degree of market acceptance of Ocaliva for PBC and, if approved, OCA for liver fibrosis due to NASH or our other product candidates among physicians, patients and healthcare payors; the availability of adequate coverage and reimbursement from governmental and private healthcare payors for our products, including Ocaliva for PBC and, if approved, OCA for liver fibrosis due to NASH, and our ability to obtain adequate pricing for such products; our ability to establish and maintain effective sales, marketing and distribution capabilities, either directly or through collaborations with third parties; competition from existing drugs or new drugs that become available; our ability to prevent system failures, data breaches or violations of data protection laws; costs and outcomes relating to any disputes, governmental inquiries or investigations, regulatory proceedings, legal proceedings or litigation, including any securities, intellectual property, employment, product liability or other litigation; our collaborators’ election to pursue research, development and commercialization activities; our ability to establish and maintain relationships with collaborators with development, regulatory and commercialization expertise; our need for and ability to generate or obtain additional financing; our estimates regarding future expenses, revenues and capital requirements and the accuracy thereof; our use of cash and short-term investments; our ability to acquire, license and invest in businesses, technologies, product candidates and products; our ability to attract and retain key personnel to manage our business effectively; our ability to manage the growth of our operations, infrastructure, personnel, systems and controls; our ability to obtain and maintain adequate insurance coverage; the impact of COVID-19, including any impact on our results of operations or financial position, related quarantines and government actions, delays relating to our regulatory applications, disruptions relating to our ongoing clinical trials or involving our contract research organizations, study sites or other clinical partners, disruptions relating to our supply chain or involving our third-party manufacturers, distributors or other distribution partners, facility closures or other restrictions, and the extent and duration thereof; the impact of general U.S. and foreign economic, industry, market, regulatory or political conditions, including the potential impact of Brexit; and the other risks and uncertainties identified in our periodic filings filed with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2019 and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020.CONTACTFor more information about Intercept, please contact: Lisa DeFrancesco +1-646-565-4833 investors@interceptpharma.com Christopher Frates +1-646-757-2371 media@interceptpharma.com Source: Intercept Pharmaceuticals, Inc.
- GlobeNewswire
Intercept to Present at the 39th Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief Executive Officer of Intercept, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on Thursday, January 14, 2021 at 11:40 a.m. ET. A live webcast of the event will be available on the investor page of Intercept’s website at http://ir.interceptpharma.com. An audio archive of the webcast will also be available on Intercept’s website for approximately two weeks.About Intercept Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.CONTACTFor more information about Intercept, please contact: Investor inquiries: investors@interceptpharma.com Media inquiries: media@interceptpharma.comSource: Intercept Pharmaceuticals, Inc.
- ACCESSWIRE
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ICPT, BSX and QIWI
NEW YORK, NY / ACCESSWIRE / January 4, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies.
